scholarly journals Role of Trospium chloride and tamsulosin therapy for treating patients with symptoms of over-active bladder related to benign prostatic enlargement

2020 ◽  
Vol 11 (1) ◽  
pp. 650-656
Author(s):  
Falah Mahdi Ali ◽  
Hayder Mahdi Alaridy ◽  
Ahmed Ali Obaid
Keyword(s):  
Teaching Hospitals ◽  
Benign Prostatic Enlargement ◽  
Trospium Chloride ◽  
Prostate Hyperplasia ◽  
Overactive Urinary Bladder ◽  
Prostatic Enlargement ◽  
Bladder Symptoms ◽  
Benign Prostate ◽  
Over Active Bladder

To assess the benefit and safety of composite therapy (Tamsulosin and Trospium drugs) in treating benign prostatic enlargement complain, mainly overactive urinary bladder symptoms. OBJECTIVE: The study has been designed to estimate the benefit and safety of Trospium and Tamsulosin in processing of symptoms of excessive bladder and benign prostate hyperplasia (BPH). Patients and Methods: Prospective clinical trial study conducted at Al-Diwaniya teaching hospitals and private clinics from march 2016 to march 2017, to patients BPH and bothersome symptoms. 60 patients were treated with Tamsulocin and 60 patients were treated by Tamsulocin and Trospium. RESULTS: Median scores of IPSS, OABSS, and QOL proved no big difference between two study sets before staring treatment (P = 0.544), (P = 0.287) , (P = 0.668) consecutively. After one month, both treatments led to a big reduction in IPSS, OABSS median score; (P < 0.001), (P < 0.001). Following three months, both treatments resulted in significant reduction in IPSS (P < 0.001), OABSS (P < 0.001), QOL result, (P < 0.001) consecutively. Conclusion: These results suggest which treatment with Trospium and tamsulosin therapy provides benefit for men with natural - Syndrome of the acute urinary tract and benign enlarged prostate.

scholarly journals Canine benign hyperplasia prostate on male pug dog

2019 ◽  
Vol 3 (3) ◽  
pp. 49-50
Author(s):  
Zulfa Ichsanniyati R. Ciwi Fadhlillah ◽  
I Nengah Yogiswari ◽  
Siti Zaenab ◽  
Deni Noviana ◽  
Sukmasari Arifah
Keyword(s):  
Ultrasound Examination ◽  
Benign Prostate Hyperplasia ◽  
Blood Chemistry ◽  
Prostate Hyperplasia ◽  
Mild Anemia ◽  
Prostate Enlargement ◽  
Prostate Size ◽  
Abdominal Palpation ◽  
Prostatic Enlargement ◽  
Benign Prostate

An 9-years-old male pug was examined for stranguria and letargic in one week. The dog has no testicles as the owner claimed that the dog had been castrated a few years ago. Abdominal palpation shows bladder retention filled with urine but no blockage was found. Urine sedimentation contained blood and few unknown crystal. Hematology showed mild anemia and leukocytosis while blood chemistry only found mild hyperglobulinemia. Radiography showed prostate enlargement. Ultrasound examination was showing mild nephrolithiasis, cystitis and prostatic enlargement. Diagnosis of benign prostate hyperplasia is suspected but doubtful because the animal has been castrated. Differential diagnose was prostatic cysts, infection and cancer. The dog received finasteride 1 mg/kg twice a day orally for 60 days and antibiotic. Urine catheter was temporarily installed to evacuate urine twice a day. Post treatment ultrasound was performed 20 days later and showed evident involution of prostate sizes. An enlarge irregular testicle was also found in right dorsolateral of bladder. Monorchid castration was performed at 60 days of finasteride. The dog was diagnosed with monorchid induce benign prostate hyperplasia from the radiography and ultrasonography. The prostate size was reduced after finasteride administration

scholarly journals Association between benign prostate hyperplasia and metabolic syndrome in men under 60 years old: a meta-analysis

2019 ◽  
Vol 47 (11) ◽  
pp. 5389-5399
Author(s):  
Shuiqing Wu ◽  
Haiqing He ◽  
Yinhuai Wang ◽  
Ran Xu ◽  
Bin Zhu ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Web Of Science ◽  
Benign Prostate Hyperplasia ◽  
Prostate Volume ◽  
Meta Analysis ◽  
Prostate Hyperplasia ◽  
Younger Men ◽  
Key Words Metabolic Syndrome ◽  
Benign Prostate

Objective To assess the potential relationship between benign prostate hyperplasia (BPH) and metabolic syndrome in men under 60 years old. Methods We searched the Medline, Embase, and Web of Science databases for studies of patients with metabolic syndrome and BPH using the key words ‘metabolic syndrome’, ‘benign prostatic hyperplasia’, and ‘BPH’. The odds ratios (ORs) and 95% confidence intervals (95%CIs) were extracted from the included studies and the role of metabolic syndrome in BPH and its characteristics (International Prostate Symptom Score (IPSS), total prostate volume (TPV), postvoid residual (PVR)) were evaluated by meta-analysis. Results Six comparative studies comprising 61,826 individuals were identified and included in this meta-analysis. There were significant correlations between metabolic syndrome and BPH (OR = 1.24, 95%CI = 1.19–1.29), clinical BPH (OR = 1.37, 95%CI = 1.03–1.70), and TPV (OR = 2.34, 95%CI = 1.25–3.42). However, there was no significant association between metabolic syndrome and IPSS (OR = 1.19, 95%CI = 0.35–2.04) or PVR (OR = 2.15, 95% CI = 0.95–3.34). Conclusions These results indicate that metabolic syndrome is significantly and positively correlated with the incidence of BPH in younger men aged <60 years. However, there was no significant relationship between metabolic syndrome and BPH-related symptoms.

The Potential Role of a Self-management Intervention for Benign Prostate Hyperplasia

Urology ◽  
2012 ◽  
Vol 79 (6) ◽  
pp. 1385-1389 ◽  
Author(s):  
Ye Chen ◽  
Xiaowei Zhang ◽  
Xiaowei Hu ◽  
Yanqing Deng ◽  
Jie Chen ◽  
...  
Keyword(s):  
Potential Role ◽  
Benign Prostate Hyperplasia ◽  
Self Management ◽  
Prostate Hyperplasia ◽  
Management Intervention ◽  
Benign Prostate
Sign in / Sign up

Export Citation Format

Share Document